119 related articles for article (PubMed ID: 27036019)
1. Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability.
Moraes L; Galrão AL; Rubió I; Cerutti JM
Oncotarget; 2016 May; 7(18):25960-70. PubMed ID: 27036019
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
Kondo T; Nakazawa T; Ma D; Niu D; Mochizuki K; Kawasaki T; Nakamura N; Yamane T; Kobayashi M; Katoh R
Lab Invest; 2009 Jul; 89(7):791-9. PubMed ID: 19506552
[TBL] [Abstract][Full Text] [Related]
4. ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence.
Latini FR; Hemerly JP; Freitas BC; Oler G; Riggins GJ; Cerutti JM
BMC Cancer; 2011 Jan; 11():11. PubMed ID: 21223585
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
[TBL] [Abstract][Full Text] [Related]
6. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
7. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
8. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
9. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a.
Qiang W; Zhao Y; Yang Q; Liu W; Guan H; Lv S; Ji M; Shi B; Hou P
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1163-72. PubMed ID: 24684457
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic mechanisms modulate thyroid transcription factor 1-mediated transcription of the surfactant protein B gene.
Cao Y; Vo T; Millien G; Tagne JB; Kotton D; Mason RJ; Williams MC; Ramirez MI
J Biol Chem; 2010 Jan; 285(3):2152-64. PubMed ID: 19906647
[TBL] [Abstract][Full Text] [Related]
12. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
Deng G; Chen A; Pong E; Kim YS
Oncogene; 2001 Oct; 20(48):7120-7. PubMed ID: 11704838
[TBL] [Abstract][Full Text] [Related]
13. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas.
Mahdiannasser M; Haghpanah V; Damavandi E; Kabuli M; Tavangar SM; Larijani B; Ghadami M
Mol Biol Rep; 2020 Mar; 47(3):2161-2169. PubMed ID: 32072403
[TBL] [Abstract][Full Text] [Related]
14. A Positive Feedback Loop Between DICER1 and Differentiation Transcription Factors Is Important for Thyroid Tumorigenesis.
Ramírez-Moya J; Santisteban P
Thyroid; 2021 Jun; 31(6):912-921. PubMed ID: 33176626
[No Abstract] [Full Text] [Related]
15. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Cameron EE; Bachman KE; Myöhänen S; Herman JG; Baylin SB
Nat Genet; 1999 Jan; 21(1):103-7. PubMed ID: 9916800
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors.
Galrão AL; Camargo RY; Friguglietti CU; Moraes L; Cerutti JM; Serrano-Nascimento C; Suzuki MF; Medeiros-Neto G; Rubio IG
J Clin Endocrinol Metab; 2014 Jun; 99(6):E944-52. PubMed ID: 24432988
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma.
Huang Y; de la Chapelle A; Pellegata NS
Int J Cancer; 2003 May; 104(6):735-44. PubMed ID: 12640681
[TBL] [Abstract][Full Text] [Related]
18. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.
Venkataraman GM; Yatin M; Marcinek R; Ain KB
J Clin Endocrinol Metab; 1999 Jul; 84(7):2449-57. PubMed ID: 10404820
[TBL] [Abstract][Full Text] [Related]
19. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
